Oncolys BioPharma Inc.
4588オンコリスバイオファーマ株式会社
Latest half-year results
First half · fiscal year to 2026-12 · filed 2026-08-07For the first half of the fiscal year to 2026-12: Revenue ¥0.5 billion (+1662.4% YoY), Ordinary income ¥-0.8 billion, Net income ¥-0.8 billion.
| This period | Year on year | |
|---|---|---|
| Revenue | ¥503m | +1662.4% |
| Ordinary profit | −¥761m | — |
| Net profit to owners | −¥762m | — |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4588/earnings-releases.
Financials
Japan GAAP · non-consolidated · fiscal year to 2025-12-31- Revenue
- ¥29m
- Net income
- −¥2.1bn
- ROE
- —
- Equity ratio
- 87.6%
- Dividend / share
- —
- Employees
- 38
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | ¥29m | −¥2,058m | ¥4,556m | ¥4,000m | — | ¥-80 | −¥1,941m |
| 2024-12-31 | ¥31m | −¥1,685m | ¥3,199m | ¥2,752m | — | ¥-77.17 | −¥2,020m |
| 2023-12-31 | ¥63m | −¥1,939m | ¥2,041m | ¥1,474m | — | ¥-108.92 | −¥1,337m |
| 2022-12-31 | ¥976m | −¥1,149m | ¥2,651m | ¥2,159m | — | ¥-66.31 | −¥1,717m |
| 2021-12-31 | ¥642m | −¥1,615m | ¥4,292m | ¥3,594m | — | ¥-95.5 | −¥1,742m |
Indicators
Computed by us from filings · fiscal year to 2025-12-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | — | — |
| Ordinary margin | -71.8575 | 0.1 |
| Equity ratio, % | 87.6 | 97 |
| Revenue growth | -0.0904 | 7.3 |
| Net income growth | -0.2216 | 21.8 |
| Operating cash flow / assets | -0.426 | 0.9 |
Results wording balance: -1.00. Proprietary text method; it describes the wording only and does not interpret context.
Interest example: if all ¥300m of reported debt repriced by 50 basis points, a year's interest would rise by ¥1m. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.
Via /v1/companies/4588/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4588/votingOwnership changes
All companies →- 2026-05-20
individual filer cut holdings in Oncolys BioPharma Inc. (4588) to 3.91% from 5.04%, below the 5% threshold.
- 2026-02-05
Morgan Stanley MUFG Securities Co., Ltd. cut holdings in Oncolys BioPharma Inc. (4588) to 2.77% from 5.56%, below the 5% threshold.
- 2026-01-21
Morgan Stanley MUFG Securities Co., Ltd. reduced holdings in Oncolys BioPharma Inc. (4588) to 5.56% from 5.79%.
- 2026-01-16
individual filer disclosed a 5.04% stake in Oncolys BioPharma Inc. (4588), crossing the 5% reporting threshold.
- 2026-01-08
Morgan Stanley MUFG Securities Co., Ltd. disclosed a 5.79% stake in Oncolys BioPharma Inc. (4588), crossing the 5% reporting threshold.
- 2025-11-21
SMBC Nikko Securities Inc. cut holdings in Oncolys BioPharma Inc. (4588) to 4.58% from 9.08%, below the 5% threshold.
- 2025-10-27
SMBC Nikko Securities Inc. reduced holdings in Oncolys BioPharma Inc. (4588) to 9.08% from 10.17%.
- 2025-10-27
Holdings of SMBC Nikko Securities Inc. in Oncolys BioPharma Inc. (4588) moved below 10% (10.17% -> 9.08%).
- 2025-10-17
SMBC Nikko Securities Inc. reduced holdings in Oncolys BioPharma Inc. (4588) to 10.17% from 10.85%.
- 2025-10-14
SMBC Nikko Securities Inc. reduced holdings in Oncolys BioPharma Inc. (4588) to 10.85% from 11.94%.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| individual filer | 2025-11-10 – 2026-05-14 | +165,000 | +0.55pt | — | — |
| SMBC日興証券株式会社 | 2023-05-26 – 2025-10-20 | +4,430,200 | +17.49pt | — | — |
| 株式会社 三井住友銀行 | 2023-06-28 – 2025-10-20 | 0 | 0.00pt | — | — |
| Evo Fund | 2024-06-14 – 2024-10-16 | +706,000 | +2.83pt | ¥567.75 | ¥540–610 |
| Evolution Capital Management LLC | 2024-06-14 – 2024-10-16 | +706,000 | +2.83pt | ¥567.75 | ¥540–610 |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4588/trades.
5% filings
Large shareholding reports on 4588| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-05-20 | individual filer | 3.91% | −1.13pt | pure investment |
| 2026-02-05 | Morgan Stanley MUFG Securities Co., Ltd. | 2.77% | −2.79pt | — |
| 2026-01-21 | Morgan Stanley MUFG Securities Co., Ltd. | 5.56% | −0.23pt | — |
| 2026-01-16 | individual filer | 5.04% | — | pure investment |
| 2026-01-08 | Morgan Stanley MUFG Securities Co., Ltd. | 5.79% | — | — |
| 2025-11-21 | SMBC Nikko Securities Inc. | 4.58% | −4.50pt | — |
| 2025-10-27 | SMBC Nikko Securities Inc. | 9.08% | −1.09pt | — |
| 2025-10-17 | SMBC Nikko Securities Inc. | 10.17% | −0.68pt | — |
| 2025-10-14 | SMBC Nikko Securities Inc. | 10.85% | −1.09pt | — |
| 2025-10-06 | SMBC Nikko Securities Inc. | 11.94% | −0.89pt | — |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- — issues
- Book value
- —
- Sold in the year
- — — issues
- Bought in the year
- — — issues
- Mutual, both reports
- 0
- Held by listed cos.
- 1
Held by: Astellas Pharma Inc. 4503
Purposes, all holdings and mutual flags via /v1/companies/4588/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2025-12-31| Shareholder | Shares | Ratio |
|---|---|---|
| アステラス製薬株式会社 | 727,200 | 2.48% |
| モルガン・スタンレーMUFG証券株式会社 | 653,700 | 2.23% |
| individual holder | 520,700 | 1.77% |
| YUANTA SECURITIES CO., LTD-RETAIL ACCOUNT | 388,400 | 1.32% |
| individual holder | 300,000 | 1.02% |
| 株式会社SBI証券 | 287,714 | 0.98% |
| individual holder | 272,200 | 0.92% |
| 野村證券株式会社 | 271,670 | 0.92% |
| UBS証券株式会社 | 267,454 | 0.91% |
| individual holder | 255,100 | 0.87% |
U.S. funds holding 4588
SEC Form N-PORT, reports to 2026-07-311 U.S. funds held 1,600 shares worth $0.0m.
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Neuroscience and Healthcare ETF iShares Trust | 1,600 | $0.0m | 0.480% | 2026-07-31 |
Up to 25 funds per stock via the API.
Get this as JSON
GET /v1/companies/4588
GET /v1/companies/4588/financials
GET /v1/companies/4588/details
GET /v1/companies/4588/segments
GET /v1/companies/4588/voting
GET /v1/companies/4588/tender-offers
GET /v1/companies/4588/indicators
GET /v1/companies/4588/earnings-releases
GET /v1/events?ticker=4588
GET /v1/companies/4588/trades
GET /v1/companies/4588/cross-holdings
GET /v1/companies/4588/brief